KRAS and cancer: A carefully selected panel of private and shared cancer-related mutations (e.g. common driver mutations in genes such as KRAS, SMAD4, TP53) identified by WES that bind to the HLA class I and II restriction elements of the patient constitute the formulation of some PCVs (27, 69–72).